Feed LUCD
LU

Lucid Diagnostics Inc.

LUCD · NASDAQ

$0.89 +4.63% (+$0.04)
1M -15.49%
Market Cap $161.2M
P/E Ratio -
Div. Yield -
ROE 404.34%

Bulios Fair Price

$1.32

47.9% upside

Trenutna cena

$0.89

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica LUCD trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/S 29.61x
P/B 14.75x
P/E N/A
Growth
78 /100
Growing
Rev. growth 131.97%
Book val. growth 22.00%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 25.79%
Net margin 959.76%
FCF margin 866.56%
Quality
2 /100
Poor
ROIC 141.44%
ROE 404.34%
Asset turnover 0.14x
Debt
19 /100
High
Debt/Equity 2.28x
Current ratio 1.33x
Int. coverage -2,902.28x
Stability
50 /100
Moderate
Beta 1.10x
Rev. volatility 291.06%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o LUCD
Online

O podjetju

Lucid Diagnostics Inc. is a biotechnology company focused on developing diagnostic technologies and tests. The company specializes in diagnostics and disease detection, particularly in the field of gastroenterology. Lucid Diagnostics develops advanced diagnostic tests and devices that enable precise and rapid determination of patients' conditions and identification of potential diseases. The company emphasizes research and development to provide the medical industry with innovative tools and technologies to improve diagnostics and patient care. Lucid Diagnostics aims to contribute to better health outcomes and quality of life for patients through its diagnostic innovations. Lucid Diagnostics Inc. shares may be an attractive investment opportunity for investors interested in the biotechnology sector and seeking an investment in a company focused on the development of diagnostic technologies with the potential to enhance medical care.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Medical - Devices

CEO

Lishan Aklog

Employees

82

Headquarters

New York City

Prihajajoči dogodki

11 NOV.

Earnings

Upcoming earnings report

49d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.